Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder - 2020-01131

niversitaetsmedizin Goettingen0 个研究点目标入组 50 人开始时间: 2024年7月2日最近更新: 2024年8月21日

试验速览

暂无简介。

•Patients with BED according to DSM-5, Male or female patients aged between 18 and 40 (the upper age limit was chosen to minimise potential confounding effects by hormonal changes related to menopause), Written informed consent obtained according to international guidelines and local laws, Ability to understand the nature of the trial and the trial related procedures and to comply with them.

•systemic (i.v. or oral) glucocorticoid treatment within the last 3 months, known pheochromocytoma, Simultaneous participation in another interventional trial, Pregnant or breastfeeding females, current diagnosis of a psychotic, bipolar, or substance use disorder, severe somatic illness (e.g. cancer, cardiovascular disease, instable diabetes mellitus; blood pressure = 160/100 mmHg at rest and/or current treatment of hypertensive crisis within last 6 months), current or planned use of psychotropic medication (during the period of the study), current or planned psychotherapy (during the period of the study), known hypersensitivity to hydrocortisone, known hereditary galactose intolerance, known lactase deficiency, known glucose-galactose malabsorption

发起方

niversitaetsmedizin Goettingen